Table 3.

Univariable and multivariable analysis

Candidate factorUnivariable analysisMultivariable analysis
PFSOSPFSOS
HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
Age >60 y4.53 (1.99-10.28)<.0017.50 (2.63-21.35)<.0012.51 (0.51-12.42).259
Male0.72 (0.39-1.34).3020.68 (0.34-1.34).268
Elevated serum LDH2.21 (1.11-4.38).0232.43 (1.14-5.19).0140.98 (0.20-4.86).9761.54 (0.18-12.98).690
Stage (II vs I)2.60 (1.39-4.90).0032.35 (1.19-4.63).0140.75 (0.16-3.62).7230.32 (0.04-2.85).304
Extranodal sites1.07 (0.57-2.00).8311.16 (0.59-2.31).660
Site (supra- vs infradiaphragmatic)1.01 (0.53-1.90).981.09 (0.55-2.18).800
Ki670.85 (0.44-1.64).6220.88 (0.44-1.79).730
Bulk disease2.10 (1.06-4.16).0332.05 (0.97- 4.32).063.67 (1.00-13.60).0503.69 (0.67-20.33).134
COO0.63 (0.33-1.20).1590.55 (0.27-1.13).1030.94 (0.18-4.90).9370.58 (0.05-6.22).652
DH1.21 (0.27-5.31).8040.61 (0.08-4.73).6391.34 (0.18-10.62).7530.68 (0.04-12.58).792
DE1.27 (0.58-2.81).5521.40 (0.60-3.30).4391.58 (0.35-7.24).5551.92 (0.25-15.04).533
Stage-modified IPI (n = 92)
 Low risk
 Intermediate risk2.95 (1.22-7.15).0202.57 (0.93-7.11).063
 High risk5.37 (2.29-12.62)<.0016.19 (2.43-15.77)<.001
  • Bold indicates statistically significant results.